Financial Counselors Inc. Has $267,000 Stake in Becton, Dickinson and Company (NYSE:BDX)

Financial Counselors Inc. reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 13.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,107 shares of the medical instruments supplier’s stock after selling 165 shares during the quarter. Financial Counselors Inc.’s holdings in Becton, Dickinson and Company were worth $267,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Public Sector Pension Investment Board lifted its stake in Becton, Dickinson and Company by 12.5% in the 3rd quarter. Public Sector Pension Investment Board now owns 12,566 shares of the medical instruments supplier’s stock valued at $3,030,000 after acquiring an additional 1,400 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Becton, Dickinson and Company by 6.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 70,906 shares of the medical instruments supplier’s stock valued at $17,095,000 after purchasing an additional 4,114 shares during the last quarter. Providence Capital Advisors LLC lifted its position in shares of Becton, Dickinson and Company by 1.2% in the third quarter. Providence Capital Advisors LLC now owns 18,740 shares of the medical instruments supplier’s stock worth $4,518,000 after purchasing an additional 216 shares in the last quarter. CreativeOne Wealth LLC boosted its holdings in Becton, Dickinson and Company by 147.5% during the third quarter. CreativeOne Wealth LLC now owns 2,185 shares of the medical instruments supplier’s stock worth $527,000 after purchasing an additional 1,302 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund grew its position in Becton, Dickinson and Company by 2.0% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 157,038 shares of the medical instruments supplier’s stock valued at $37,862,000 after purchasing an additional 3,035 shares in the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently commented on BDX. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Evercore ISI raised their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Finally, Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, Becton, Dickinson and Company presently has an average rating of “Buy” and an average price target of $283.00.

Becton, Dickinson and Company Trading Down 0.0 %

Becton, Dickinson and Company stock opened at $221.90 on Monday. The stock has a 50-day simple moving average of $234.16 and a 200 day simple moving average of $234.10. The stock has a market capitalization of $64.14 billion, a P/E ratio of 37.36, a PEG ratio of 1.65 and a beta of 0.43. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $249.89.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The business had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same period in the previous year, the firm earned $3.42 EPS. The firm’s revenue was up 6.9% compared to the same quarter last year. Analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th will be paid a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.87%. The ex-dividend date is Monday, December 9th. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 63.97%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.